Multiple Sclerosis

Roland Martin, Reinhard Hohlfeld, H. F. McFarland

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

This chapter presents a discussion on multiple sclerosis (MS). MS is the most frequent demyelinating central nervous system (CNS) disease among Northern Europeans and Northern Americans. The etiology of MS is still unclear, but it is now widely accepted that an autoimmune response directed at myelin antigens contributes to the pathogenesis. Findings supporting this hypothesis include the histopathology of the MS lesion, which reflects an inflammatory process consisting mainly of lymphocytes and macrophages, the association with certain HLA-class II antigens, and parallels to a well-described animal model for autoimmune demyelinating disease, experimental allergic encephalomyelitis (EAE). MS is a disease of young adulthood and mostly manifests between the ages of 20 and 40 years. Only a few percent of patients have the disease develop before 15 and after 55 years of age. Females are affected 1.5-2 times more frequently than males. Most often, MS begins as a relapsing remitting disease characterized by acute exacerbations or episodes of acute neurological dysfunction that improve, often completely, over a period of weeks without any treatment. The discussion on currently applied therapeutic strategies include glucocorticoids, interferon-beta (IFN-β), glatiramer acetate, intravenous immunoglobulins (iv-IG), and so on. The discussion on immunosuppressive treatment also includes mitoxantrone (MIX), azathioprine (AZA), cyclophosphamide (CTX), cyclosporine A (CSA), and others.

Original languageEnglish (US)
Title of host publicationNeurological Disorders: Course and Treatment: Second Edition
PublisherElsevier Inc.
Pages677-706
Number of pages30
ISBN (Print)9780121258313
DOIs
StatePublished - 2003
Externally publishedYes

Fingerprint

Multiple Sclerosis
Mitoxantrone
Autoimmune Experimental Encephalomyelitis
Interferon-beta
Central Nervous System Diseases
Intravenous Immunoglobulins
Histocompatibility Antigens Class II
Azathioprine
Demyelinating Diseases
Acute Disease
Immunosuppressive Agents
Myelin Sheath
Autoimmunity
Cyclophosphamide
Cyclosporine
Glucocorticoids
Autoimmune Diseases
Therapeutics
Animal Models
Macrophages

ASJC Scopus subject areas

  • Medicine(all)
  • Dentistry(all)

Cite this

Martin, R., Hohlfeld, R., & McFarland, H. F. (2003). Multiple Sclerosis. In Neurological Disorders: Course and Treatment: Second Edition (pp. 677-706). Elsevier Inc.. https://doi.org/10.1016/B978-012125831-3/50248-3

Multiple Sclerosis. / Martin, Roland; Hohlfeld, Reinhard; McFarland, H. F.

Neurological Disorders: Course and Treatment: Second Edition. Elsevier Inc., 2003. p. 677-706.

Research output: Chapter in Book/Report/Conference proceedingChapter

Martin, R, Hohlfeld, R & McFarland, HF 2003, Multiple Sclerosis. in Neurological Disorders: Course and Treatment: Second Edition. Elsevier Inc., pp. 677-706. https://doi.org/10.1016/B978-012125831-3/50248-3
Martin R, Hohlfeld R, McFarland HF. Multiple Sclerosis. In Neurological Disorders: Course and Treatment: Second Edition. Elsevier Inc. 2003. p. 677-706 https://doi.org/10.1016/B978-012125831-3/50248-3
Martin, Roland ; Hohlfeld, Reinhard ; McFarland, H. F. / Multiple Sclerosis. Neurological Disorders: Course and Treatment: Second Edition. Elsevier Inc., 2003. pp. 677-706
@inbook{3431b152ee2b470a8c028b592ae7950e,
title = "Multiple Sclerosis",
abstract = "This chapter presents a discussion on multiple sclerosis (MS). MS is the most frequent demyelinating central nervous system (CNS) disease among Northern Europeans and Northern Americans. The etiology of MS is still unclear, but it is now widely accepted that an autoimmune response directed at myelin antigens contributes to the pathogenesis. Findings supporting this hypothesis include the histopathology of the MS lesion, which reflects an inflammatory process consisting mainly of lymphocytes and macrophages, the association with certain HLA-class II antigens, and parallels to a well-described animal model for autoimmune demyelinating disease, experimental allergic encephalomyelitis (EAE). MS is a disease of young adulthood and mostly manifests between the ages of 20 and 40 years. Only a few percent of patients have the disease develop before 15 and after 55 years of age. Females are affected 1.5-2 times more frequently than males. Most often, MS begins as a relapsing remitting disease characterized by acute exacerbations or episodes of acute neurological dysfunction that improve, often completely, over a period of weeks without any treatment. The discussion on currently applied therapeutic strategies include glucocorticoids, interferon-beta (IFN-β), glatiramer acetate, intravenous immunoglobulins (iv-IG), and so on. The discussion on immunosuppressive treatment also includes mitoxantrone (MIX), azathioprine (AZA), cyclophosphamide (CTX), cyclosporine A (CSA), and others.",
author = "Roland Martin and Reinhard Hohlfeld and McFarland, {H. F.}",
year = "2003",
doi = "10.1016/B978-012125831-3/50248-3",
language = "English (US)",
isbn = "9780121258313",
pages = "677--706",
booktitle = "Neurological Disorders: Course and Treatment: Second Edition",
publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - Multiple Sclerosis

AU - Martin, Roland

AU - Hohlfeld, Reinhard

AU - McFarland, H. F.

PY - 2003

Y1 - 2003

N2 - This chapter presents a discussion on multiple sclerosis (MS). MS is the most frequent demyelinating central nervous system (CNS) disease among Northern Europeans and Northern Americans. The etiology of MS is still unclear, but it is now widely accepted that an autoimmune response directed at myelin antigens contributes to the pathogenesis. Findings supporting this hypothesis include the histopathology of the MS lesion, which reflects an inflammatory process consisting mainly of lymphocytes and macrophages, the association with certain HLA-class II antigens, and parallels to a well-described animal model for autoimmune demyelinating disease, experimental allergic encephalomyelitis (EAE). MS is a disease of young adulthood and mostly manifests between the ages of 20 and 40 years. Only a few percent of patients have the disease develop before 15 and after 55 years of age. Females are affected 1.5-2 times more frequently than males. Most often, MS begins as a relapsing remitting disease characterized by acute exacerbations or episodes of acute neurological dysfunction that improve, often completely, over a period of weeks without any treatment. The discussion on currently applied therapeutic strategies include glucocorticoids, interferon-beta (IFN-β), glatiramer acetate, intravenous immunoglobulins (iv-IG), and so on. The discussion on immunosuppressive treatment also includes mitoxantrone (MIX), azathioprine (AZA), cyclophosphamide (CTX), cyclosporine A (CSA), and others.

AB - This chapter presents a discussion on multiple sclerosis (MS). MS is the most frequent demyelinating central nervous system (CNS) disease among Northern Europeans and Northern Americans. The etiology of MS is still unclear, but it is now widely accepted that an autoimmune response directed at myelin antigens contributes to the pathogenesis. Findings supporting this hypothesis include the histopathology of the MS lesion, which reflects an inflammatory process consisting mainly of lymphocytes and macrophages, the association with certain HLA-class II antigens, and parallels to a well-described animal model for autoimmune demyelinating disease, experimental allergic encephalomyelitis (EAE). MS is a disease of young adulthood and mostly manifests between the ages of 20 and 40 years. Only a few percent of patients have the disease develop before 15 and after 55 years of age. Females are affected 1.5-2 times more frequently than males. Most often, MS begins as a relapsing remitting disease characterized by acute exacerbations or episodes of acute neurological dysfunction that improve, often completely, over a period of weeks without any treatment. The discussion on currently applied therapeutic strategies include glucocorticoids, interferon-beta (IFN-β), glatiramer acetate, intravenous immunoglobulins (iv-IG), and so on. The discussion on immunosuppressive treatment also includes mitoxantrone (MIX), azathioprine (AZA), cyclophosphamide (CTX), cyclosporine A (CSA), and others.

UR - http://www.scopus.com/inward/record.url?scp=34547693537&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547693537&partnerID=8YFLogxK

U2 - 10.1016/B978-012125831-3/50248-3

DO - 10.1016/B978-012125831-3/50248-3

M3 - Chapter

AN - SCOPUS:34547693537

SN - 9780121258313

SP - 677

EP - 706

BT - Neurological Disorders: Course and Treatment: Second Edition

PB - Elsevier Inc.

ER -